FDAnews
www.fdanews.com/articles/96516-emea-committee-for-orphan-medicinal-products-recommends-orphan-medicinal-product-designation-for-lux-biosciences-rsquo-lx211-for-the-treatment-of-uveitis

EMEA Committee for Orphan Medicinal Products Recommends Orphan Medicinal Product Designation for Lux Biosciences’ LX211 for the Treatment of Uveitis

July 31, 2007

Lux Biosciences, Inc., a privately held biotechnology company specialized in the field of ophthalmic diseases, announced that the EMEA committee for Orphan Medicinal Products has adopted a positive opinion on orphan medicinal product designation for the company’s investigational therapeutic, LX211, for the treatment of chronic, non-infectious uveitis.
BusinessWire